心脏手术中血小板输注是否独立影响出血与不良结局
该回顾性观察研究纳入23,860例心脏手术患者,将169例仅早期术中输注血小板者与507例倾向性评分匹配的无早期输血者比较。结果发现血小板输注组出血量更少,但更多需要血管活性药物、延长机械通气与ICU停留及后续血制品输注,而再干预、血栓栓塞并发症、感染、器官衰竭和死亡率无差异。
要点
- 早期术中血小板输注与更少出血量相关,但未增加血栓栓塞或死亡率。
- 血小板输注组更多需要血管活性药、延长通气和ICU停留及后续输血。
- 该研究为回顾性观察,不能确立因果关系。
核心结论
- 心脏手术患者术中接受血小板输注与更少出血量相关,但更多需要血管活性药物、延长机械通气、延长ICU停留和术后血制品输注。
- 早期血小板输注与再干预、血栓栓塞并发症、感染、器官衰竭或死亡率无关。
研究设计与样本
- 回顾性观察研究,分析23,860例心脏手术患者。
- 干预组定义为早期(体外循环后仍在手术室)接受一次血小板输注且无其他输血的患者,共169例。
- 参照组为无早期输血且倾向性评分最匹配的患者,按1:3匹配,共507例。
主要发现
- 干预组与参照组在再干预、血栓栓塞并发症、感染、器官衰竭和死亡率方面无差异。
- 干预组出血量更少。
- 干预组更多需要血管活性药物:139/169(82%) vs 370/507(74%),OR 1.65,95%CI 1.05-2.58。
- 干预组更多延长机械通气:92/169(54%) vs 226/507(45%),OR 1.47,95%CI 1.03-2.11。
- 干预组更多延长ICU停留:95/169(56%) vs 240/507(46%),OR 1.49,95%CI 1.04-2.12。
关键数值与推荐
- 干预组红细胞输注75/169(44%) vs 参照组145/507(34%),OR 1.55,95%CI 1.08-2.23。
- 干预组血浆输注29/169(17%) vs 参照组23/507(7.3%),OR 2.63,95%CI 1.50-4.63。
- 干预组血小板输注72/169(43%) vs 参照组25/507(4.3%),OR 16.4,95%CI 9.3-28.9。
临床怎么用
- 心脏手术术中血小板输注需权衡减少出血与增加血管活性药物、延长通气和ICU停留及后续输血的风险。
- 该研究结果提示早期血小板输注未增加血栓栓塞并发症、感染、器官衰竭或死亡率。
局限性
- 回顾性分析,可能存在未测量的混杂因素。
- 干预组样本量较小(169例),参照组507例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Conflicting results have been reported concerning the effect of platelet transfusion on several outcomes. The aim of this study was to assess the independent effect of a single early intraoperative platelet transfusion on bleeding and adverse outcomes in cardiac surgery patients. METHODS: For this observational study, 23,860 cardiac surgery patients were analyzed. Patients who received one early (shortly after cardiopulmonary bypass while still in the operating room) platelet transfusion, and no other transfusions, were defined as the intervention group. By matching the intervention group 1:3 to patients who received no early transfusion with most comparable propensity scores, the reference group was identified. RESULTS: The intervention group comprised 169 patients and the reference group 507. No difference between the groups was observed concerning reinterventions, thromboembolic complications, infections, organ failure, and mortality. However, patients in the intervention group experienced less blood loss and required vasoactive medication 139 of 169 (82%) versus 370 of 507 (74%; odds ratio, 1.65; 95% CI, 1.05 to 2.58), prolonged mechanical ventilation 92 of 169 (54%) versus 226 of 507 (45%; odds ratio, 1.47; 94% CI, 1.03 to 2.11), prolonged intensive care 95 of 169 (56%) versus 240 of 507 (46%; odds ratio, 1.49; 95% CI, 1.04 to 2.12), erythrocytes 75 of 169 (44%) versus 145 of 507 (34%; odds ratio, 1.55; 95% CI, 1.08 to 2.23), plasma 29 of 169 (17%) versus 23 of 507 (7.3%; odds ratio, 2.63; 95% CI, 1.50-4.63), and platelets 72 of 169 (43%) versus 25 of 507 (4.3%; odds ratio, 16.4; 95% CI, 9.3-28.9) more often compared to the reference group. CONCLUSIONS: In this retrospective analysis, cardiac surgery patients receiving platelet transfusion in the operating room experienced less blood loss and more often required vasoactive medication, prolonged ventilation, prolonged intensive care, and blood products postoperatively. However, early platelet transfusion was not associated with reinterventions, thromboembolic complications, infections, organ failure, or mortality.
引用
- van Hout FM, Hogervorst EK, Rosseel PM, et al. Does a Platelet Transfusion Independently Affect Bleeding and Adverse Outcomes in Cardiac Surgery? Anesthesiology. 2017. PMID: 28092320. doi:10.1097/ALN.0000000000001518
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。